Ipamorelin 5mg

Ipamorelin 5mg — Selective GH Secretagogue

When Raun et al. characterized Ipamorelin in 1998, they called it “the first growth hormone secretagogue receptor agonist with a selectivity for GH release similar to that displayed by GHRH” (European Journal of Endocrinology; PubMed 9849822). That selectivity is what defines this compound. Earlier GH-releasing peptides like GHRP-6 and GHRP-2 stimulated growth hormone but also pushed cortisol and prolactin levels higher. Ipamorelin does not — at GH-releasing concentrations in preclinical models, cortisol and prolactin remain at baseline levels. Buy Ipamorelin 5mg

Ipamorelin 5mg Specifications

Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular Formula	C38H49N9O5
Molecular Weight	711.85 g/mol
CAS Number	170851-70-4
PubChem CID	9831659
Purity	≥99% (HPLC)
Form	Lyophilized powder
Quantity	5mg per vial

Pharmacology and Receptor Signaling

Ipamorelin 5mg binds to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed primarily in anterior pituitary somatotrophs. The binding triggers a phospholipase C-mediated signaling cascade: IP3/DAG release, intracellular calcium mobilization, and protein kinase C (PKC) activation, culminating in growth hormone exocytosis. EC50 has been measured at 1.3 nmol/L in rat pituitary cell assays, with peak GH response occurring at approximately 40 minutes post-administration and a circulating half-life of approximately 2 hours (Gobburu et al., Pharmaceutical Research, 1999). Buy Ipamorelin 5mg

What distinguishes ipamorelin from earlier GHS-R agonists (hexarelin, GHRP-6, GHRP-2) is its signaling selectivity. While those compounds activate GHS-R1a and also engage other pathways that elevate cortisol and prolactin, ipamorelin produces minimal cross-reactivity at GH-releasing concentrations. This selectivity makes it a valuable tool for researchers studying isolated GHS-R1a-mediated somatotroph activation without confounding adrenocorticotropic or lactotropic effects (Sinha et al., Transl Androl Urol, 2020; PMC7108996).

Research Applications Beyond Growth Hormone

The published literature on ipamorelin extends well beyond somatotroph activation. Svensson et al. examined its effects in bone mineral density studies using dual-energy X-ray absorptiometry (DEXA) and peripheral quantitative computed tomography (pQCT) in murine models, documenting changes in cortical and trabecular bone parameters (Svensson et al., The Journal of Endocrinology, 2000). Greenwood-Van Meerveld et al. investigated ipamorelin in postoperative gastric dysmotility models, where GHS-R1a agonism was associated with effects on gastric emptying rate and smooth muscle contractility (J Exp Pharmacol, 2012; PubMed 27186124).

Additional research contexts include the study of GHS-R1a constitutive activity (the receptor signals at approximately 50% of maximal capacity even without ligand binding), inverse agonism, and biased signaling — areas where ipamorelin serves as a reference agonist for characterizing receptor pharmacology (Holst et al., Molecular Endocrinology, 2003; PubMed 12893882).

Key Research Applications

• Selective GHS-R1a agonism and somatotroph signaling cascade characterization
• Comparative secretagogue studies — selectivity profiling against GHRP-6, GHRP-2, hexarelin
• Dual-pathway growth hormone axis research when paired with GHRH receptor agonists
• GHS-R1a constitutive activity and biased agonism investigations
• Bone metabolism and mineral density research models
• Gastrointestinal motility and smooth muscle contractility studies

Ipamorelin + CJC-1295: Dual-Receptor Axis Research

Ipamorelin (GHS-R1a agonist) and CJC-1295 (GHRH receptor agonist) target different receptors within the same somatotropic axis. The published literature routinely examines these compounds together for dual-pathway somatotroph activation studies, as the two receptor systems converge on complementary intracellular signaling mechanisms in pituitary somatotrophs. Peptide Bio Sciences LTD offers the CJC-IPA blend for researchers investigating this paired approach.

Ipamorelin 5mg is Frequently Paired With

• CJC-1295 No DAC — Available as CJC-IPA Blend.
• Tesamorelin 5mg — Available as Ipa/Tesa Blend.
• Sermorelin 5mg — Alternative GHRH analog pairing.

Quality and Testing

Every lot of Peptide Bio Sciences LTD ipamorelin is manufactured in the United States and verified by independent third-party analytical laboratories. Testing includes HPLC purity analysis (≥99%), mass spectrometry for molecular identity and sequence confirmation, and endotoxin screening. Batch-specific Certificates of Analysis (COA) are available through the Peptide Bio Sciences LTD COA Portal.

Storage

• Lyophilized: Store at -20°C, protected from light and moisture
• Reconstituted: 2-8°C, use within 30 days
• Avoid repeated freeze-thaw cycles

References

1. Raun K, et al. European Journal of Endocrinology. 1998;139(5):552-561. PubMed 9849822
2. Sinha DK, et al. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMC7108996
3. Gobburu JVS, et al. Pharmaceutical Research. 1999;16:1412-1416.
4. Holst B, et al. Molecular Endocrinology. 2003;17(11):2201-2210. PubMed 12893882
5. Svensson J, et al. The Journal of Endocrinology. 2000.
6. Greenwood-Van Meerveld B, et al. J Exp Pharmacol. 2012;4:149-155. PubMed 27186124

For laboratory research use only. Not for human or veterinary use.